LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

1.27 2.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.2

Max

1.27

Belangrijke statistieken

By Trading Economics

Inkomsten

5.6M

-4.7M

Verkoop

6.1M

6.3M

Winstmarge

-74.681

Werknemers

23

EBITDA

7.3M

-5.1M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+169.84% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

49M

88M

Vorige openingsprijs

-1.15

Vorige sluitingsprijs

1.27

Nieuwssentiment

By Acuity

100%

0%

358 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 sep 2025, 22:39 UTC

Acquisities, Fusies, Overnames

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sep 2025, 16:43 UTC

Belangrijke Marktbewegers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sep 2025, 16:42 UTC

Belangrijke Marktbewegers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sep 2025, 16:35 UTC

Belangrijke Marktbewegers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sep 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 sep 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sep 2025, 23:34 UTC

Marktinformatie

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sep 2025, 22:48 UTC

Marktinformatie

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sep 2025, 22:12 UTC

Acquisities, Fusies, Overnames

CSL Expects Commercial Launch in 2029

15 sep 2025, 22:12 UTC

Acquisities, Fusies, Overnames

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sep 2025, 22:11 UTC

Acquisities, Fusies, Overnames

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sep 2025, 22:11 UTC

Acquisities, Fusies, Overnames

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sep 2025, 22:10 UTC

Acquisities, Fusies, Overnames

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sep 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sep 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sep 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sep 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 sep 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sep 2025, 19:14 UTC

Marktinformatie

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sep 2025, 18:16 UTC

Marktinformatie

Gold Powers to New High -- Market Talk

15 sep 2025, 18:05 UTC

Marktinformatie

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sep 2025, 17:50 UTC

Acquisities, Fusies, Overnames

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sep 2025, 17:10 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 sep 2025, 17:10 UTC

Marktinformatie

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sep 2025, 16:52 UTC

Marktinformatie

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sep 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 sep 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

169.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.4 USD  169.84%

Hoogste 5.5 USD

Laagste 1.5 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

358 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat